STXS - Robotic Systems for MedicineStereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
Disclaimer: This is not financial advice.
Opportunity Highlight: Stereotaxis Regulatory Milestones Ahead
Over the next 10 months, Stereotaxis is anticipated to receive major regulatory approvals that could significantly impact its market position and stock value. Investors should note the following key points in evaluating this opportunity:
Expect Gradual Movement: Current trading volume is low, indicating that significant price movements might unfold more gradually than in more volatile plays. This suggests a more long-term investment approach may be suitable.
Market Sentiment Dependency: The success of this investment is closely tied to the overall bullish sentiment in the market. A market correction could adversely affect the potential for this play to unfold as expected.
Critical Resistance at $2.9 : For Stereotaxis to demonstrate a stronger upward momentum, it must surpass the resistance level around $2.9. Breaking through this barrier is essential for further positive price action.
Risk Management Strategies:
Stop Loss (SL) Strategy : To mitigate potential losses, consider setting a stop loss at just below $2.2.
Take Profit (TP) Targets: Depending on market conditions and individual risk tolerance, profit-taking targets are tentatively set at approximately $3.2, $3.9, and an optimistic $4.9.
Analytical Resources: For a more detailed analysis, including technical indicators and trend predictions, refer to the chart provided. The chart contains essential information that could guide trading decisions.
Trading Approach: Given the expected gradual nature of the stock's movement and its dependency on broader market trends, traders should proceed with caution. Monitoring market sentiment and being prepared to adjust strategies in response to significant market shifts will be crucial.
STXS trade ideas
5/13/24 - $stxs - beware if you blindly own this; downside > up5/13/24 - vrockstar - incredibly lump results, and surprising stock remains bid even after the last two whiffs (big whiffs too). cool tech. would like to see this win, but burning 10 mm a year w/ 20 mm in the bank, some complications in the stack and overall worth north of $150 mm... is a tough one for me when i can buy profitable software w/ better mgns, growing sustainably and struggle to command even 4x sales. i get it. i get it. different industries. but in this mkt a lot of these smaller (call it sub 5 bn - though i recognize this one is substantially smaller) names are getting lumped together until powpowpow in 2H. in which case, i'd AT MOST be paying 3x sales and probably closer to 2x, which still puts this stock -50% from here. burning a post to caution anyone who owns this who hasn't done some deeper DD that the math, trends and recent stock performance seem to spell more downside, not upside.
Stereotaxis; I am not a financial analyst, not a stock analyst, not even a robot analyst. This is my opinion, and you should do research on anything you put money into, and my ramblings are not that research.
With that said, this is my personal take on this little company that builds robots that do heart surgery. In the following presentation, if you think I know a thing or two about hearts, and anything medically related to hearts, please know that I dissected a cat in senior anatomy class and that is about the extent of my medical knowledge.
The Wax Poetic
Normally I would put the science part of my analysis here, but I can't do science on this. I really don't know much about robotics systems much past a roomba. Furthermore, they build robots for TAVRs, and I really only know the basics on this from a secondary source with a mix of news articles and light, extremely light, medical journal articles. So when I say things like, this company has an exponential growth margin with the ability to become a 100+billion dollar corporation that 70% of the 65+ age group are going to meet, well yeah, its bullshit. But that's the moon for them, I just need them to get off the ground. Luckily, this doesn't even rely on them, except for their ability to manufacture and train, so any major price changes are years away.
TAVRs- Transcatheter aortic valve replacement: $35k procedure (in the USA) that is being done on a growing amount of patients not yet in need of major open heart surgery, but those still needing a surgical intervention. This is rather common where medical options have failed, or the person is old or hasn't taken good care of themselves. As the general age of the population increases, as it has been, and the general access to higher level medical care is increased, as it has been in the US with the rise of the mid-level medical provider (Nurse practitioners and Physician's Assistants), those needing advanced medical or surgical treatments for their heart and vascular system will increase. Furthermore, as more and more TAVR surgeries are being done and the access to them is increased, the need for an accomplished and precise surgeon is going to be necessary. This is where Stereotaxis excels. I am going to be really honest with y'all, surgeons fucking suck. That isn't a joke. An "excellent" surgeon is a surgeon who just makes less mistakes. Robots are going to take over surgeries because they aren't just better, they are perfect. Or rather, they will be, eventually, when they have been developed and tested enough.
And then enters Stereotaxis. A company making a robot that lets a trained expert in the TAVR procedure to do them, aka an advanced mid-level? Or maybe allowing a surgical expert in the TAVR procedure, an expert on performing surgeries using the robot and an actual surgeon to perform it from thousands of miles away? Aaaaaaand they did that! In China no less. If you want to talk about a market needing access to higher level medical procedures in a developed country, then focus that discussion on China. I have no doubt that the medical boom underway in America is going to advance in China at a much greater rate. Being on the edge of that advance is amazing. This is a market that is going to see a boom. I have no idea if Stereotaxis is the company to do it, but I don't see anyone else positioning for it.
On top of all of this, they are developing automated imaging robots. This doesn't just help in pushing advanced medical access to more remote or suburban regions, but helps urban centers deal with a costly and timely process. The company doesn't just already have a massive blockbuster on their hands, they have a studio jam packed with ideas, vision, and the engineers to make it happen?
The Company
This is where I will caution you. I am a science first dude, if you are a medical or science company, you need to keep science with you, otherwise you are a product company. Products fail, science just has more to discover. Stereotaxis is a product company. Or rather it has the shell of a product company. Do not sue me if I get this wrong, but this is my interpretation: A young doctor does well for himself, an esteemed medical expert, does research as well. Sells a company to Pfizer, makes a lot of money. His son turns out to be a math wiz, pretty good at analyzing mathematical patterns, has a nose for stocks. The doctor has money, starts an investment firm. Son joins investment firm specializing in research and analysis of medical device and medical companies. Son sees a star, tires of being an analyst, wants to start a company, a brand, he wants to be a technoking one day. So the son buys the company, sets up the right people to manage growth, works deals, business driving business.
I have no doubt that there is a crew of top notch scientists, engineers, coders and doctors inside the shell. I just don't know how much they get a say in the company, or the products anymore. Think Apple, once they lost some of their all star inside the shell team, they turned from overpriced but good to overpriced and absolute trash. Do I trust Stereotaxis to become the next Apple and do that? No. But I can definitely keep an eye on Stereotaxis and look out for it's competitors, because someone is getting a piece of this pie.
I would suggest a visit to the company's website for investors. The presentation is business garbage, but that is what we are here for, ain't it.
The Play
I don't see a short term driver of massive growth outside the current resistance bands. Overall, I see the next stretch of action getting +/-20-30%, presenting various short term trades, but the true value might be in pulling this as a true long and avoiding massive taxes. Furthermore, my motto is to balance everything, so having a nice potential long could be nice. The fundamentals are nice, it has low float, low volume and low market cap. If any company wants to acquire, it would be impossible without a massive increase in value over current as a huge amount is owned by the CEO and director (Father/son of their hedge fund), thus forcing them to pay a lot or to start their own development, announcing it, and causing media and hype on Stereotaxis, bumping them up.
The Fundamentals
As of 3/31/21 with a stock price of $6.79, they have a market capitalization of $500 million.
19% of the company is owned by the CEO's dad's hedge fund (that he also runs). Without this, the son is easy prey to remove with a competing ownership stake. That and the CEO seems arrogant enough to never not believe in himself, with smart enough to maybe make it happen, so he has been buying more and more of the company.
The next 5 institutions own 8-4% of the float as well, and they have all been buying more recently. Oh, and they all look like the CEO's friends or are actual Directors of the company.
The financials also give the appearance that the last price decrease was retail/day trader driven.
It looks like the float is drying up, the price could get more and more volatile with a general lean upwards, unless some catastrophic causes someone to be margin called, so there is volatility both ways!
A competitor, Intuitive Surgical, does robots for laprascopic/endoscopic procedures, has a market cap of 88 billion. While Intuitive is a much more developed, possibly better, company that deserves its valuation, it doesn't have the tech in PR or outward development to enter any of the same space. While there are a handful of other great companies all developing and working on it, I view Stereotaxis as a solid workhorse for any diverse portfolio.
They have no debt, plenty of free cash and are on their way to the green.
Thank you, and as always, please leave criticism or comments, things you want me to touch on more, etc. Always do your own research, internet is full of strangers, weirdos and liars.
$STXS can rise in the next daysContextual immersion trading strategy idea.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease in the United States and internationally.
The demand for shares of the company looks higher than the supply.
This and other conditions can cause a rise in the share price in the next days.
So I opened a long position from $7,95;
stop-loss — $6,89.
Information about take-profits will be later.
Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision.
Always do your own analysis before making deals. When you use any materials, do not rely on blind trust.
You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy.
If you like my content, you can subscribe to the news and receive my fresh ideas.
Thanks for being with me!